How does retatrutide work?
Retatrutide simultaneously activates the GLP-1, GIP, and glucagon receptors, combining appetite suppression with direct hepatic energy expenditure — the mechanism associated with the large weight and liver-fat reductions reported in clinical trials.
Retatrutide receptor pathways at a glance
A three-receptor design
Retatrutide is an engineered 39-amino-acid peptide that engages three receptors at once: GLP-1 (satiety and insulin), GIP (incretin amplification), and glucagon (hepatic energy expenditure). The triple-action profile is sometimes called a "GGG" tri-agonist.
The design builds on the dual GLP-1/GIP class by adding glucagon receptor activation, which increases hepatic thermogenesis and energy expenditure — something appetite suppression alone cannot do. That third arm is part of why retatrutide has produced the largest body-composition shifts reported in this class.
What the published pharmacology shows
Jastreboff et al. (NEJM, 2023) published the landmark Phase 2 data: 24.2% mean weight loss at 48 weeks with the 12 mg dose, with more than 90% of participants losing at least 10%. Sanyal et al. (Nature Medicine, 2024) then reported up to 82.4% reduction in liver fat in MASLD trials. The pivotal Phase 3 trial TRIUMPH-1 (NCT05929066, 2025) reported 28.3% mean weight loss at 80 weeks with the 12 mg dose (45.3% of participants ≥30%), confirming the Phase 2 trajectory. The peptide is hepatically metabolised without CYP involvement, so drug-drug interactions are minimal.
Frequently asked questions
What is retatrutide?
Retatrutide is an investigational triple agonist — it activates the GLP-1, GIP and glucagon receptors — developed by Eli Lilly and still in clinical trials (not approved anywhere). Retatrutide is the research-grade form of this retatrutide peptide, supplied as a lyophilised powder strictly for in-vitro and preclinical laboratory research. It is not an approved medicine.
What does retatrutide do?
In published research retatrutide activates three receptors at once — GLP-1 and GIP (satiety, insulin secretion, adipose effects) plus glucagon (hepatic energy expenditure and liver-fat clearance). The triple mechanism is what distinguishes it from dual (tirzepatide) and single (semaglutide) agonists. These are research findings for the molecule, not human-use guidance.
Why is the glucagon receptor useful here? Glucagon raises blood sugar, right?
It does, but at the right intensity and in combination with GLP-1, glucagon receptor agonism stimulates hepatic energy expenditure and fat oxidation without significant net glucose elevation. The GLP-1 arm offsets any glycemic downside while the glucagon arm delivers unique energy-balance effects.
References
Related research
All compounds referenced are supplied for laboratory research use only and are not for human or veterinary use. Nothing on this page is medical advice. Every order, account and payment completes on the canonical store at new-u.io.